Dynavax pockets $30M to fund new development

Dynavax Technologies has gained $30 million in new financing to help accelerate the development of its allergy products. Deerfield Management is providing the money, which will go to finance a late-stage ragweed trial and preclinical programs for peanut and cat allergies. The Phase III study of Tolamba will enroll about 300 volunteers. In the financing deal, Dynavax will not have to repay up to $9 million for the study if it proves unsuccessful.

- check out the release
- here's the AP report for more information

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.